DE2937489A1 - Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase - Google Patents
Arzneimittel zur behandlung hypertoner funktionszustaende der harnblaseInfo
- Publication number
- DE2937489A1 DE2937489A1 DE19792937489 DE2937489A DE2937489A1 DE 2937489 A1 DE2937489 A1 DE 2937489A1 DE 19792937489 DE19792937489 DE 19792937489 DE 2937489 A DE2937489 A DE 2937489A DE 2937489 A1 DE2937489 A1 DE 2937489A1
- Authority
- DE
- Germany
- Prior art keywords
- bladder
- active ingredient
- urinary bladder
- medicines
- functional states
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims description 12
- 210000003932 urinary bladder Anatomy 0.000 claims description 27
- 239000004480 active ingredient Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 239000000969 carrier Substances 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 18
- 229930003347 Atropine Natural products 0.000 description 6
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229960000396 atropine Drugs 0.000 description 6
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010036018 Pollakiuria Diseases 0.000 description 5
- 206010029446 nocturia Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 230000003153 cholinolytic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- UVKFSMBPRQBNCH-UHFFFAOYSA-M 4,4-diphenylbutan-2-yl-ethyl-dimethylazanium;bromide Chemical compound [Br-].C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 UVKFSMBPRQBNCH-UHFFFAOYSA-M 0.000 description 2
- 208000028048 Accommodation disease Diseases 0.000 description 2
- 206010005052 Bladder irritation Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960002493 emepronium bromide Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000012153 long-term therapy Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- 206010004663 Biliary colic Diseases 0.000 description 1
- 206010005063 Bladder pain Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- UKXSKSHDVLQNKG-UHFFFAOYSA-N benzilic acid Chemical class C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CC=C1 UKXSKSHDVLQNKG-UHFFFAOYSA-N 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001558 histaminolytic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 201000003890 low compliance bladder Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003170 musculotropic effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229950009846 scopolamine butylbromide Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 206010046494 urge incontinence Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD78208336A DD139212A1 (de) | 1978-10-09 | 1978-10-09 | Verfahren zur herstellung eines neuen arzneimittels aus alpha,alpha-diphenyl-alpha-alkoxyessigsaeure-1-methylpiperidyl-4-ester-derivaten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2937489A1 true DE2937489A1 (de) | 1980-04-17 |
| DE2937489C2 DE2937489C2 (enrdf_load_stackoverflow) | 1990-08-02 |
Family
ID=5514770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792937489 Granted DE2937489A1 (de) | 1978-10-09 | 1979-09-17 | Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5555117A (enrdf_load_stackoverflow) |
| CH (1) | CH644016A5 (enrdf_load_stackoverflow) |
| DD (1) | DD139212A1 (enrdf_load_stackoverflow) |
| DE (1) | DE2937489A1 (enrdf_load_stackoverflow) |
| GB (1) | GB2031727B (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102743A3 (de) * | 2001-06-17 | 2003-03-13 | Berolina Drug Dev Ab | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3742580C1 (de) * | 1987-12-16 | 1989-05-11 | Schaper & Bruemmer Gmbh | Verwendung des alpha,alpha-Diphenyl-alpha-(3-carboxy-propionyloxy)-essigsaeure-4-(N-methylpiperidyl)-esters zur Behandlung hypertoner Funktionszustaende im Bereich der Harnblase |
| US7851633B2 (en) | 2006-06-09 | 2010-12-14 | Beiersdorf Ag | Piperidinium compounds and cosmetic compositions containing them |
| US9505717B2 (en) | 2012-01-30 | 2016-11-29 | Taiho Pharmaceutical Co., Ltd. | Acetic acid ester compound or salt thereof |
| EP2851073B1 (en) | 2012-05-15 | 2016-11-09 | Taiho Pharmaceutical Co., Ltd. | Prophylactic agent and/or therapeutic agent for stress urinary incontinence |
| AU2014271739B2 (en) * | 2013-05-30 | 2016-07-28 | Taiho Pharmaceutical Co., Ltd. | Novel fluorinated benzilic acid ester compound, and salt thereof |
-
1978
- 1978-10-09 DD DD78208336A patent/DD139212A1/xx unknown
-
1979
- 1979-09-17 DE DE19792937489 patent/DE2937489A1/de active Granted
- 1979-09-28 GB GB7933790A patent/GB2031727B/en not_active Expired
- 1979-10-05 CH CH900479A patent/CH644016A5/de not_active IP Right Cessation
- 1979-10-06 JP JP12934579A patent/JPS5555117A/ja active Granted
Non-Patent Citations (1)
| Title |
|---|
| NEGWER, M.: Org.-Chem. Arzneimittel und ihre Synonyma, Nr. 4450, 4601, 4656, 4657, 4858, 4956, 5134, 6576, 1978 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102743A3 (de) * | 2001-06-17 | 2003-03-13 | Berolina Drug Dev Ab | Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| US7943176B2 (en) | 2001-10-09 | 2011-05-17 | Apogepha Arzneimittel Gmbh | Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| DD139212A1 (de) | 1979-12-19 |
| GB2031727B (en) | 1982-11-03 |
| JPS5555117A (en) | 1980-04-22 |
| JPS6251242B2 (enrdf_load_stackoverflow) | 1987-10-29 |
| DE2937489C2 (enrdf_load_stackoverflow) | 1990-08-02 |
| CH644016A5 (de) | 1984-07-13 |
| GB2031727A (en) | 1980-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69720985T2 (de) | Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung | |
| DE69518729T2 (de) | Stickstoffoxyd abgebendes präparat zur behandlung von analen erkrankungen | |
| DE60009346T2 (de) | Buprenorphin enthaltende analgetische zusammensetzungen | |
| AT401615B (de) | Verwendung von speziellen 5ht3-antagonisten zur herstellung von arzneimitteln | |
| DE60019814T2 (de) | Pharmazeutische kombinationen enthaltend tegaserod und omeprazole und ihre verwendung zur behandlung gastrointestinaler krankheiten | |
| DE3855323T2 (de) | Galenische 2-beta-Mimetik-Formen für die per- und sublinguale Verabreichung | |
| DE2823174A1 (de) | Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose | |
| DE60211913T2 (de) | Aryl- (oder heteroaryl-) azolylcarbynolderivatve zur behandlung von harninkontinenz | |
| DE3603564A1 (de) | Pharmazeutische praeparate mit analgetrischer wirksamkeit, sowie deren herstellung und verwendung | |
| DE3604575A1 (de) | Kombination von flupirtin und anticholinergisch wirkenden spasmolytika | |
| DE2520978C3 (de) | Dosierungseinheit einer festen, oral zu verabreichenden Arzneiform von wasserlöslichen Xanthin-Derivaten | |
| DE2937489A1 (de) | Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase | |
| EP0306846A2 (de) | Neue synergistische Kombination bestehend aus einem Phosphodiesterase-Hemmer und einem Thromboxan-A2-Antagonisten und deren Verwendung bzw. Herstellung | |
| DE2759171A1 (de) | Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor | |
| EP0132595B1 (de) | Tokolytisches Mittel | |
| DE2451933C2 (enrdf_load_stackoverflow) | ||
| WO2000032199A1 (de) | Verwendung von galanthamin und galanthaminderivaten bei akuten funktionellen hirnschäden | |
| EP2120918B1 (de) | Pharmazeutische zusammensetzung zur behandlung von inkontinenz | |
| DE1617336C2 (de) | Arzneimittel gegen Angina pectoris | |
| DE69426317T2 (de) | Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation | |
| DE3406837C2 (enrdf_load_stackoverflow) | ||
| DE2828200A1 (de) | Verwendung von tetramisole oder levamisole oder deren salzen bei der bekaempfung von scabies (kraetze) | |
| DE2636328A1 (de) | Arzneimittel | |
| EP0870499A1 (de) | Orale Anwendung von (+)-0-Demethyltramadol als Schmerzmittel | |
| DE2055930A1 (de) | Verbesserte orale Applikationsform von Raubasin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8127 | New person/name/address of the applicant |
Owner name: VEB SAECHSISCHES SERUMWERK DRESDEN, DDR 8012 DRESD |
|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: APOGEPHA ARZNEIMITTEL GMBH, O-8019 DRESDEN, DE |
|
| 8381 | Inventor (new situation) |
Free format text: SCHUBERT, GEB. RICHTER, GERTRUD, DIPL.-BIOL. DR.RER.NAT., O-8051 DRESDEN, DE STARKE, CHRISTIAN, DIPL.-CHEM., O-8053 DRESDEN, DE PEIN, ECKHARDT, DR., 3410 NORTHEIM, DE |
|
| V448 | Application of spc |
Free format text: PRODUCT NAME: PROPIVERINHYDROCHLORID; REGISTRATION NO/DATE: NICHT BEKANNT, 19981021 Spc suppl protection certif: 198 75 042 Filing date: 19981021 |
|
| V448 | Application of spc |
Free format text: PRODUCT NAME: PROPIVERINHYDROCHLORID; REGISTRATION NO/DATE: 44279.00.00, 19981221 Spc suppl protection certif: 199 75 038 Filing date: 19990515 |
|
| V457 | Spc granted |
Free format text: PRODUCT NAME: PROPIVERINHYDROCHLORID; REGISTRATION NO/DATE: 44279.00.00, 19981221 Spc suppl protection certif: 199 75 038 Filing date: 19990515 |
|
| V454 | Spc application withdrawn or to be regarded as withdrawn |
Free format text: PRODUCT NAME: PROPIVERINHYDROCHLORID; REGISTRATION NO/DATE: NICHT BEKANNT, 19981021 Spc suppl protection certif: 198 75 042 Filing date: 19981021 |
|
| V464 | Spc expired |
Free format text: PRODUCT NAME: PROPIVERINHYDROCHLORID; REGISTRATION NO/DATE: 44279.00.00, 19981221 Spc suppl protection certif: 199 75 038 Filing date: 19990515 |